NR2E1 and retinitis pigmentosa: For the Müller glia, a promoter that expresses in both the Müller glia and retinal pigment epithelium (RLBP1) has been fully developed and is currently in use in a clinical trial for the treatment of RLBP1 retinitis pigmentosa using rAAV8 and subretinal administration [8, 104]; whereas Ple316 (NR2E1) resulted expression in the Müller glia with off-target expression in amacrine cells using rAAV9 and intravitreal or intravenous administration.